Last reviewed · How we verify

bupivacaine 0.25 % injection

Ain Shams University · FDA-approved active Small molecule

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses.

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses. Used for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks.

At a glance

Generic namebupivacaine 0.25 % injection
SponsorAin Shams University
Drug classLocal anesthetic (amide class)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine reversibly binds to and inactivates voltage-gated sodium channels on the inner surface of nerve cell membranes, thereby preventing depolarization and action potential generation. This blocks conduction of sensory, motor, and autonomic nerve impulses in a dose-dependent manner. The drug is long-acting due to its high lipophilicity and protein binding, allowing sustained local anesthesia at the injection site.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: